Colorectal cancer

• There is a point of optimism to build upon, as the Pancreatic Cancer Action Network (PanCAN) has stated the five-year survival rate for pancreatic cancer has increased to 13% .
• "Combining pelareorep with mFOLFIRINOX represents an expansion of our existing pancreatic cancer program and maximizes the potential of pelareorep-based combination therapies to benefit pancreatic cancer patients."
• It will focus on patients with pancreatic cancer, HER2-negative metastatic breast cancer, metastatic castration-resistant prostate cancer (mCRPC), and platinum-resistant ovarian cancer (PROC).
• Nuvation is already undergoing dosing in the Phase 1 monotherapy study of NUV-868 in solid tumors in patients with pancreatic cancer, ovarian cancer, metastatic castration-resistant prostate cancer (mCRPC), triple-negative breast cancer and other solid tumors.

• Available through the Roche navify Algorithm Suite, LGI-Flag is a groundbreaking AI-driven algorithm used to flag individuals at risk for lower GI disorders that warrant further evaluation.
• "Capital Digestive Care is committed to enabling the digital transformation of healthcare, in order to provide a more personalized, convenient and predictive continuum-of-care for patients," said Michael Weinstein, M.D., CEO of Capital Digestive Care.
• Now, we have a means to more precisely identify those at high risk of lower GI disorders, including colorectal cancer so they may avoid the devastating effects of the disease through increased screening and earlier detection and treatment."
• "This helps advance that mission by offering a highly effective and clinically validated machine-learning-based algorithm to identify those at increased risk of a wide array of lower GI disorders, including colorectal cancer."

• Contrary to common perception, cancer does not always announce its presence through overt symptoms or obvious signs.
• While even silent cancers can sometimes be aggressive and advance rapidly, they can also remain dormant for years or even decades.
• Some prostate, breast and thyroid cancers, for example, often evolve slowly without obvious symptoms or spreading beyond the original area.

The importance of early diagnosis

• Whatever the cancer, it’s always important to get an early diagnosis though – and for silent cancers, this is obviously a challenge.
• But such symptoms can be misinterpreted or easily dismissed, which contributes to delayed diagnosis and treatment.
• Fortunately, in many countries including the UK, we have screening tests for diseases like breast or colon cancer, to increase early diagnoses.
• Early diagnosis is a key factor for successful cancer treatment.

Biomarker discovery

• From molecular profiling to liquid biopsy techniques (blood tests to diagnose cancer), innovative approaches are reshaping the landscape of cancer diagnosis, offering new avenues for personalised and precision medicine.
• For example, I worked with a team using blood tests to identify cancers in more than 1,000 women recalled after screening for mammography.
• Although there’s increasing awareness and use of this approach in Europe, it isn’t standard in the UK.

Justin Stebbing does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.

• BERKELEY, US – MAINZ, Germany – February 21st, 2024 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a leader in molecular genetics diagnostic solutions for early cancer detection, announced today a strategic partnership with TomaLab to launch the Company’s flagship product, ColoAlert® in Italy.
• TomaLab is one of Italy’s premier biotechnology laboratories and is based in Milan.
• "TomaLab is the ideal partner to bring our pioneering product to Italy given its state-of-the-art facilities and commitment to innovative healthcare solutions, " said Guido Baechler, CEO of Mainz Biomed.
• "We are thrilled to collaborate with Mainz Biomed to incorporate ColoAlert® into our laboratory procedures."